Therapeutic applications of interleukin-2
著者
書誌事項
Therapeutic applications of interleukin-2
（Basic and clinical oncology, v. 2）
Marcel Dekker, c1993
- :pbc
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Covering everything from basic science to disease-specific clinical trials, current applications and future directions, this book discusses the novel biological response modifier interleukin-2. This immunoactive therapy is designed for use in the treatment of metastatic renal cancer and, possibly, melanoma and other malignancies. Examining the value and toxic manifestations of different treatment regimens, this text: describes the biochemistry of the IL-2 receptor, the activation of natural killer cells and the lymphokine-activated killer (LAK) cell phenomenon; explicates tumour-infiltrating lymphocytes and the effect of IL-2 on in vitro assays of immune function; emphasizes high-dose IL-2 therapy in renal cell carcinoma and malignant melanoma; reviews in detail IL-2 treatment of other solid tumours and haematologic malignancies; illustrates the use of lower dose regimens, regional administration and combinations of IL-2 with other therapies; elucidates toxicities associated with IL-2, their pathogenesis and clinical management; and highlights future developments, including gene therapy and the co-administration of cytokine antagonists to reduce toxicity.
目次
- Part 1 Immunologic effects of IL-2: IL-2 and its receptor - structure, function, and regulation of expression, Thomas R. Malek and Nancy S. Gutgsell
- properties of IL-2-activated lymphocytes, Elizabeth Ann Grimm
- properties of human tumour-infiltrating lymphocytes, Kyogo Itoh and Charles M. Balch
- pre-clinical studies with Interleukin-2 in tumour-bearing animals, Bishan S. Charak and Amitabha Mazumder
- biologic effects of Interleukin-2
- administration on the immune system, David H. Boldt and Thomas M. Ellis. Part 2 Clinical trials with Interleukin-2: overview, Robert I. Fisher
- high-dose IL-2 treatment of melanoma, Joseph A. Sparano and Janice P. Dutcher
- high-dose IL-2 treatment of renal cell carcinoma, Margaret C. Sunderland and Geoffrey R. Weiss
- low-dose IL-2 in cancer therapy, Vera Malkovska et al
- Interleukin-2 in the treatment of hematologic malignancies, Mark C. Benyunes and Alexander Fefer
- Interleukin-2 in malignancies other than melanoma and renal cell carcinoma, Mario Sznol and Michael J. Hawkins
- locoregional administration of IL-2 and/or LAK cells, Walter J. Urba
- adoptive immunotherapy with tumour-infiltrating lymphocytes, Richard Kradin
- Interleukin-2 in combination with other biologic agents, Mario Sznol et al
- Interleukin-2 and chemotherapy, Lawrence E. Flaherty and Michael B. Atkins
- clinical studies in Europe, Gerrit Stoter et al
- Euro-cetus-coordinated clinical trials, Christopher R. Franks et al. Part 3 Toxicity of Interleukin-2 immunotherapy: overview, James W. Mier
- the clinical toxicities of high-dose Interleukin-2, Kim Margolin
- pathogenesis of the Interleukin-2 induced vascular leak syndrome, James W. Mier
- hemodynamic and cardiovascular effects of Interleukin-2, Ellen R. Gaynor and Richard I. Fisher
- autoimmune disorders induced by Interleukin-2 therapy, Michael B. Atkins
- infectious complications associated with Interleukin-2, Mark S. Klempner and David R. Syndman
- nursing management of patients receiving high-dose IL-2 therapy, Jody Goult Tsevat et al. Part 4 Interleukin-2 therapy - future directions: enhancement of the antineoplastic activity of Interleukin-2, David R. Parkinson
- abrogation of Interleukin-2 toxicity, James W. Mier.
「Nielsen BookData」 より